For decades, the scientific community has recognized the gut microbiome—the intricate ecosystem of bacteria and microorganisms residing within the human intestine—as a potential key player in colorectal cancer development. Yet, the complexity and variability of microbiome data have often obscured clear, reproducible links. Now, an ambitious new study spearheaded by the Mi-EOCRC consortium, which includes pioneering teams at EMBL Heidelberg, has transcended these obstacles by analyzing an unprecedented breadth of data to unearth a universal microbiome signature associated with colorectal cancer.

Garnering insights from an extensive meta-analysis of 27 studies with over 6,700 gut microbiome profiles, the researchers uncovered microbial patterns that remain consistent across diverse populations, sequencing methodologies, and age groups—illuminating a microbial footprint intrinsic to colorectal cancer itself. Their integrative approach not only encompassed stool samples but also expanded to 906 intestinal tissue specimens, revealing striking similarities between microbes colonizing tumors and those present in fecal matter.

This landmark research fundamentally shifted microbiome science by developing innovative computational tools capable of harmonizing heterogeneous datasets produced by different sequencing technologies. Such methodological rigor was critical in overcoming previous barriers of reproducibility that have long plagued microbiome studies. Central to their approach was a bespoke machine learning algorithm adept at categorizing microbiomes along a continuum from ‘healthy’ to ‘cancer-like,’ yielding a quantifiable score that can be leveraged across disparate human gut microbiome datasets, including those derived from dietary interventions.

This algorithmic precision allowed the consortium to isolate a colorectal cancer-associated microbiome signature that transcends traditional cohort boundaries. Intriguingly, the signature appears robust not only in late-stage disease but also in early-onset cases, dispelling prior uncertainty surrounding the microbiome’s role throughout the disease timeline. The discovery underscores the microbiome’s potential as an informative biomarker capable of reflecting the intricate disease ecology.

Moreover, by comparing tumor tissue microbial profiles with those detected in stool, the study illuminated how colorectal cancer’s microbial hallmarks are mirrored across sample types. Although the microbial signature was more readily detectable in advanced tumors or those proximal to the rectum, early-stage lesions exhibited a detectable microbial presence as well. This finding deepens our understanding of tumor-microbiome crosstalk and raises critical questions regarding how microbial communities might influence tumor progression via metabolic and signaling pathways.

Despite these advances, the researchers caution that pre-cancerous adenomas—often the target of preventive strategies—remain notoriously elusive in stool-derived microbiome analyses. The microbial alterations associated with adenomas were subtler and less consistent than those observed in full-fledged cancers. Sophisticated machine learning models specifically aimed at adenoma detection showed variable success across cohorts, highlighting the need for methodological refinement before such tools can make meaningful clinical contributions.

Diet emerged as another pivotal factor shaping cancer-associated microbial patterns. A compelling link was established between low dietary fiber intake and a heightened presence of the colorectal cancer microbiome signature. Conversely, dietary interventions increasing fiber consumption correlated with marked reductions in this cancer-associated microbial pattern. These findings reinforce the concept that diet—and particularly fiber—modulates the gut environment in ways that could impact cancer risk and progression, opening avenues for microbiome-focused preventive strategies rooted in nutrition.

Delving further into microbial taxonomy, the study provided high-resolution insights into Fusobacterium species, bacteria recurrently implicated in colorectal cancer. The researchers delineated notable differences among subspecies, with Fusobacterium nucleatum subsp. animalis exhibiting consistent cancer enrichment worldwide, whereas others showed distinct geographic distributions, predominantly in Asian populations. This nuanced understanding challenges the oversimplification of grouping all Fusobacteria uniformly and underscores the importance of subspecies-level resolution for future microbiome research and therapeutic targeting.

Open science was a cornerstone of this monumental undertaking. By consolidating thousands of publicly available microbiome profiles, the researchers achieved a scale of analysis previously unattainable, setting a new standard for evidence synthesis in microbiome studies. This collective data sharing facilitates reproducible science and paves the way for scalable, global approaches to understanding the microbiome’s role in human disease.

While the study stops short of proposing an immediate diagnostic application, it lays critical groundwork for the development of microbiome-informed clinical tools. Compared to existing non-invasive colorectal cancer screening tests like the fecal immunochemical test, microbiome-based classifiers are not yet on par for sensitivity or specificity. However, the reproducible microbial signature defined here could serve as a foundational reference for future machine-learning models, enabling improved risk stratification and early detection when integrated with other clinical markers.

The implications of this research ripple beyond colorectal cancer alone. The computational tools and conceptual frameworks unveiled may be applied to myriad disease contexts where the microbiome plays a role. Furthermore, the iterative feedback loop between dietary modulation and microbial signatures encourages a personalized medicine approach that incorporates lifestyle factors into disease management.

Finally, this research highlights the intricate dance between host, microbes, and environment that shapes disease landscapes. As microbiome science marches forward, studies like this exemplify the power of interdisciplinary collaboration, computational innovation, and open data stewardship to unravel complex biomedical puzzles, bringing us closer to novel interventions and preventive strategies that could transform patient outcomes worldwide.

Subject of Research: People
Article Title: Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across onset age and sequencing method
News Publication Date: 24-Jun-2026
Web References: http://dx.doi.org/10.1016/j.chom.2026.05.030
Image Credits: Daniela Velasco/EMBL
Keywords: Colorectal cancer, Human microbiota, Gut microbiota

In a groundbreaking study published in Cell Death Discovery, researchers have unveiled a novel mechanism by which Helicobacter pylori, the notorious gastric pathogen, drives the formation and persistence of gastric cancer through a process termed the “hit-and-run” legacy. This research elucidates how transient infection by H. pylori delivers a lasting epigenetic imprint on gastric epithelial cells, effectively locking these cells into a survival mode that fosters oncogenesis. The implications of these findings are profound, offering fresh insights into the molecular interplay between infection-induced epigenetic modification and cancer development, which could pave the way for revolutionary diagnostic and therapeutic strategies.

Helicobacter pylori has long been established as a principal carcinogen associated with gastric cancer, a malignancy ranking among the world’s deadliest. Traditionally, the carcinogenic potential of H. pylori has been attributed to chronic inflammation and the persistent presence of bacterial virulence factors that continuously disrupt gastric mucosa homeostasis. However, the current study challenges this paradigm by demonstrating that even transient exposure to H. pylori can induce stable, heritable epigenetic alterations that effectively “lock” the cellular genome into an aberrant state, independent of ongoing infection. This “hit-and-run” mechanism underscores the importance of early, possibly even brief, pathogen-host interactions in cancer genesis.

At the heart of this discovery is the concept of epigenetic locking—a process through which transient signals induce durable modifications in DNA methylation and histone patterns, which subsequently enforce gene expression profiles conducive to cell survival and proliferation. The group led by Sun, Hu, and Traub employed state-of-the-art genome-wide methylation profiling alongside chromatin immunoprecipitation sequencing (ChIP-seq) to map the intricate epigenetic landscapes shaped by H. pylori infection. Their findings revealed a marked enrichment of repressive histone marks on tumor suppressor gene loci and a reduction in methylation at key oncogenic enhancers, a dual mechanism that effectively enables gastric epithelial cells to bypass apoptosis and adopt a resilient phenotype.

Intriguingly, the authors identified a “survival switch” embedded within the epigenetic circuitry, which perpetuates cell viability in the hostile gastric environment despite the absence of the pathogen. This survival pathway hinges on the modulation of several critical transcription factors and downstream effectors that drive resistance to oxidative stress and immune checkpoint evasion. The persistence of this switch presents a formidable barrier to therapeutic intervention, explaining the often-observed resistance and relapse seen in conventional anti-H. pylori and chemotherapeutic regimes.

The study further explores the timing and sequence of epigenetic alterations following H. pylori infection. Temporal analysis demonstrated that initial infection triggers a wave of epigenetic remodeling within days, with key changes becoming fixed in the genome over weeks, thus confirming the durability of the modifications. This rapid “imprinting” emphasizes the need for early detection and intervention post infection to prevent the establishment of irreversible oncogenic programs.

Mechanistically, the team delved into the role of bacterial virulence factors such as CagA and VacA in orchestrating these epigenetic changes. They postulate that CagA, upon translocation into host cells, interacts with host chromatin modifiers and signaling pathways like NF-kB and STAT3, initiating cascades that culminate in altered chromatin architecture. VacA further modulates cellular metabolism and stress responses, cumulatively fixing the epigenetic landscape conducive to cancer progression.

The implications of the “hit-and-run” model extend beyond H. pylori-induced gastric cancer, provoking reconsideration of how transient infections may contribute to other epigenetically driven malignancies. This paradigm shift advocates for a broader investigation into the long-term impact of infectious insults at the epigenome level, potentially revolutionizing the standard view of tumorigenesis associated with microbial pathogens.

Therapeutically, the study stimulates the development of epigenetic-targeted approaches aimed at “unlocking” these stable aberrations. By reversing methylation patterns or disrupting the survival networks sustained by epigenetic modifications, it may become possible to sensitize tumor cells to existing chemotherapies or to immune-mediated clearance. The prospect of integrating epigenetic therapy into the clinical management of H. pylori-associated gastric cancer represents a promising frontier.

Moreover, diagnostic innovation could also benefit from these findings. Epigenetic biomarkers identified through this research may serve as early indicators of cancer risk in patients with a history of H. pylori infection, enabling stratification and personalized surveillance. The early detection of epigenetic locking signatures in gastric mucosa could dramatically improve prognosis by facilitating timely therapeutic intervention.

The study’s comprehensive exploration of epigenetic changes was bolstered by the use of gastric organoids and in vivo models, which authentically recapitulated the cellular and tissue contexts of H. pylori infection. This multi-faceted experimental design lent robust physiological relevance to the findings and highlighted the dynamic interplay between pathogen factors and host epigenomic machinery.

Collectively, this research not only deciphers the cryptic molecular legacy left by H. pylori but also refines our understanding of infection-associated carcinogenesis. The “hit-and-run” legacy paradigm sheds light on the complex, often covert, mechanisms through which transient pathogen interactions exert long-lasting oncogenic effects, shifting both scientific insight and clinical approach.

In summary, the work by Sun, Hu, Traub, and colleagues heralds a new era in gastric cancer biology, emphasizing the critical role of infection-driven epigenetic programming. As further investigations build upon this foundation, multidisciplinary efforts encompassing microbiology, epigenetics, and cancer therapeutics will be essential to translate these insights into tangible clinical applications.

The future of combatting H. pylori-associated gastric cancer lies not only in eradicating the bacteria but also in decoding and reversing the epigenetic codes it inscribes. This endeavor carries the promise of transforming patient outcomes, potentially mitigating one of the world’s most lethal cancers with strategies born from the understanding of the pathogen’s epigenetic “hit-and-run” legacy.

Subject of Research: Epigenetic mechanisms underlying the persistence and oncogenic transformation in Helicobacter pylori-associated gastric cancer.

Article Title: The “Hit-and-Run” legacy: epigenetic locking and the survival switch in H. pylori-associated gastric cancer.

Article References:
Sun, J., Hu, P., Traub, B. et al. The “Hit-and-Run” legacy: epigenetic locking and the survival switch in H. pylori-associated gastric cancer. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03210-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03210-y

For many men diagnosed with advanced prostate cancer, one of the biggest concerns is how long treatment will continue working. Although hormone therapy can slow the disease for years, prostate cancer often finds ways to adapt and eventually becomes resistant. Once this happens, treatment becomes more complicated and the risk of disease progression increases. Researchers […]

The post New Treatment Greatly Benefit Men with Aggressive Prostate Cancer appeared first on Knowridge Science Report.

In a groundbreaking study published in Nature Communications, researchers have illuminated a critical link between Fusobacterium periodonticum and the progression of colorectal cancer, unveiling a complex biochemical pathway that involves decanoic acid-mediated neutrophil chemotaxis. This discovery adds a significant piece to the puzzle of how microbial influences within the gut microenvironment contribute to tumorigenesis, potentially opening new avenues for targeted therapies against colorectal cancer.

Colorectal cancer is among the leading causes of cancer-related mortality worldwide, and although genetic factors and lifestyle influences have been extensively studied, the role of the gut microbiota has only recently come to the forefront. The study conducted by Jia, Jiang, Gong, and colleagues delves deeply into the mechanistic interactions between a specific bacterial species, Fusobacterium periodonticum, and the host immune landscape, highlighting a novel metabolic crosstalk that accelerates tumor development.

Fusobacterium periodonticum, traditionally associated with oral biofilms and periodontal disease, has increasingly been detected in colorectal cancer tissues, but its precise role in cancer biology remained unclear until now. The researchers demonstrate that this bacterium secretes decanoic acid, a medium-chain fatty acid, which acts as a chemoattractant, mobilizing neutrophils to the site of tumor inception. Neutrophils, while pivotal in innate immunity, paradoxically can induce pro-tumorigenic inflammation under certain conditions.

By employing an integrative approach combining metagenomic analyses, metabolomics, and in vivo murine models, the team traced the cascade from bacterial colonization to immune recruitment and revealed that decanoic acid engages specific chemokine receptors on neutrophils. This interaction fosters a microenvironment rich in inflammatory mediators, growth factors, and oxidative stress, all of which potentiate malignant transformation and tumor growth.

The significance of neutrophils in cancer progression is increasingly recognized, but the finding that a bacterial metabolite directly drives neutrophil chemotaxis in the colorectal milieu establishes a new paradigm. Unlike conventional chemoattractants, decanoic acid appears to uniquely modulate neutrophil behavior, enhancing their recruitment and activation state, which in turn exacerbates tissue remodeling and genomic instability within epithelial cells.

This intricate host-microbe dialogue also implicates metabolic dysregulation as a driving force. The elevated levels of decanoic acid in the tumor microenvironment underscore how bacterial metabolism intersects with host pathways, creating conditions unfavorable for normal tissue homeostasis and favorable for neoplastic transformation. The researchers adeptly demonstrate that blocking the receptors responsive to decanoic acid attenuates neutrophil infiltration and reduces tumor burden in experimental models, underscoring therapeutic potential.

Further dissection of the immune milieu revealed that neutrophils recruited by decanoic acid secrete a spectrum of cytokines and chemokines that recruit additional immune and stromal cells, contributing to a chronic inflammatory state. This inflammation not only supports tumor cell proliferation but also promotes angiogenesis and suppresses adaptive immune responses, thereby facilitating immune evasion.

The clinical implications of these findings are manifold. Understanding the role of Fusobacterium periodonticum and its metabolic products in colorectal tumorigenesis invites consideration of microbiota-targeted interventions. Strategies such as selective antibiotics, probiotics to restore microbial balance, or small molecules that inhibit decanoic acid signaling might serve as adjuncts to conventional chemotherapy or immunotherapy.

Indeed, the intersection between microbial ecology and cancer biology posits a compelling narrative wherein microorganisms are not mere bystanders but active participants orchestrating complex pathophysiological processes. The decanoic acid-driven recruitment of neutrophils exemplifies how microbial metabolites can hijack immune mechanisms, turning protective responses into facilitators of malignancy.

Moreover, the identification of decanoic acid as a pivotal mediator expands the landscape of oncogenic metabolites beyond the commonly studied short-chain fatty acids, introducing medium-chain fatty acids as critical players in tumor-immune dynamics. This underscores the importance of integrating metabolomic profiling in cancer research to uncover previously underappreciated biochemical pathways.

From a diagnostic perspective, elevated decanoic acid or markers of neutrophil activation within colorectal tissues or patient serum samples might serve as biomarkers for early detection or risk stratification. The specificity imparted by the involvement of Fusobacterium periodonticum offers a microbiota-based signature that could refine personalized medicine approaches.

The authors highlight the translational potential of targeting the decanoic acid-neutrophil axis. For instance, developing receptor antagonists or neutralizing antibodies that mitigate neutrophil chemotaxis may diminish pro-tumor inflammation without compromising host defense. Such therapies could synergize with immunomodulatory agents to reinvigorate anti-tumor immunity.

Beyond colorectal cancer, these findings prompt reevaluation of Fusobacterium periodonticum’s role in other inflammatory or neoplastic conditions associated with mucosal surfaces. The paradigms unveiled here may be applicable to understanding microbiota-driven pathogenesis in other cancers or chronic inflammatory diseases, hinting at broader biomedical relevance.

The robust experimental framework of this study, which ranges from bacterial culture to patient-derived samples and genetically engineered mouse models, strengthens the causal link and positions it as a cornerstone for future investigations. The detailed mechanistic insights provide a platform for exploring combinatorial therapies that integrate microbial manipulation and immune modulation.

In sum, Jia et al. have charted a novel territory in cancer research by elucidating how a bacterial species long recognized for its role in oral health can influence colorectal carcinogenesis through a metabolite-mediated immune recruitment mechanism. This work exemplifies the power of interdisciplinary research bridging microbiology, immunology, and oncology to unravel complex disease processes.

As research continues to unravel the intricate dance between microbiota and host immunity, the elucidation of pathways like the decanoic acid-driven neutrophil chemotaxis reaffirms the critical role of the microbiome in health and disease. Ultimately, this knowledge holds promise for innovative cancer prevention strategies that target the microbial ecosystem alongside human cells.

The implications of this research resonate beyond the laboratory, raising compelling questions about dietary modulation, microbiome management, and personalized interventions that could transform cancer prognosis. Understanding the forces that drive tumorigenesis at the intersection of microbes and immune cells is not just an intriguing scientific pursuit but a critical step toward conquering a major human health burden.

Subject of Research:
The study focuses on the interaction between Fusobacterium periodonticum and neutrophil chemotaxis mediated by decanoic acid, with implications for colorectal tumorigenesis.

Article Title:
Fusobacterium periodonticum promotes colorectal tumorigenesis via decanoic acid-driven neutrophil chemotaxis.

Article References:
Jia, X., Jiang, L., Gong, Y. et al. Fusobacterium periodonticum promotes colorectal tumorigenesis via decanoic acid-driven neutrophil chemotaxis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74591-y

Image Credits: AI Generated